Opexa Therapeutics (OPXA), a Woodlands-based biotech company specializing in the development of an innovative immunotherapy using T-cells to treat multiple sclerosis, as of April 30, 2013 has enrolled 48 patients with Secondary Progressive Multiple Sclerosis in a Phase IIb clinical test of the imilecleucel-T, autologous T-Cell Immunotherapy known as Tcelna™.
http://bionews-tx.com/news/2013/05/15/opexa-therapeutics-reports-first-quarter-2013-financial-results/
Showing posts with label Financial. Show all posts
Showing posts with label Financial. Show all posts
Wednesday, May 15, 2013
Thursday, April 25, 2013
Pain Therapeutics Reports Loss in Q1 2013 Financial Reports
Read about how Texas-based Pain Therapeutics has Reported a Loss in Q1 2013 Financial Reports.
http://bionews-tx.com/news/2013/04/25/pain-therapeutics-reports-loss-in-q1-2013-financial-reports/
Subscribe to:
Posts (Atom)